Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Archemix Corp.
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
Indoco has seen growth in Q3 FY22 based on the performance of its domestic business. Though the company hasn’t seen growth in its international segment, Indoco management says the firm is on track to perform better in the next quarter.
India’s Indoco has reported double-digit sales growth, as well as a jump in operating profit and EBITDA for its financial second quarter ended 30 September 2021. The company has seen consistent growth on the back on domestic and international launches.
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.